Zurueck zur Suche

Reporte zur Charge N254C

Verknuepft ueber VAERS_ID mit VAERSDATA, Vax und Symptoms

21Reporte angezeigt
0Todesfaelle
1Hospitalisiert
0Lebensbedrohlich
0Bleibende Schaeden
CA 7 TX 2 MI 1 OK 1 NC 1 AR 1 UT 1 MO 1 CT 1 VA 1 MA 1 HI 1

VAERS 2629723

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

moderat
Staat
MI
Alter
63,0
Geschlecht
M
Eingang
10.05.2023
Impfdatum
29.09.2022
Beginn
02.05.2023
Tage bis Beginn
215,0
Dosis
2
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: ja Disable: unbekannt ER: unbekannt Erholt: ja
Acute kidney injury Anaemia Bronchoscopy abnormal COVID-19 Colitis Computerised tomogram abdomen abnormal Computerised tomogram thorax abnormal Cytomegalovirus test Dehydration Diarrhoea Haemoglobin normal Hyperkalaemia Lung opacity Metabolic acidosis Myelosuppression Neutropenia Occult blood positive Red blood cell transfusion

Symptomtext

Discharge Provider: DO Primary Care Provider: MD Admission Date: 5/2/2023 Discharge Date: 5/9/23 PRESENTING PROBLEM: AKI (acute kidney injury) (HCC) [N17.9] HOSPITAL COURSE: 64 Yo male 3 months s/p bilateral lung transplasnt for COPD presented with complaints of worsening diarrhea. He was sent initially to OSH ER and found to have profound neutropenia, anemia, AKI with metabolic acidosis and hyperkalemia. CT thorax with new tree-in-bud opacities in RLL. Found to be Covid +. He was transferred to hospital for further management. A bronchoscopy was completed upon admission given CT changes which was positive for staph aureus. Patient was treated with 10d of abx, initially ancef then cefuroxime on dc. Additional his film array was positive for COVID. Given ongoing diarrhea symptoms which was thought to be related to COVID, treatment with remdesivir was completed. Regarding his severe AKI, this was felt to be likely from a combination of dehydration from diarrhea as well as severely high tacrolimus level also likely from diarrhea symptoms. Tacrolimus was held. AKI resolved completely after initiation of IVF and holding offending agents. Eventually tacrolimus was resumed without issue once kidney injury had resolved In addition to the AKI patient was severely neutropenic and anemic. He was given 1u RBC and hematology was consulted. After testing it was determined the cause was likely bone marrow suppression from toxic levels of his valcyte and tacrolimus. Patient was given 3 doses of neupogen inpatient and neutropenia recovered. Valcyte was eventually resumed 5/8 after CMV level was checked which was 0. For his anemia, EPO was given 5/7 and hemoglobin remained stable after 1u RBC. Stool occult blood was found to be positive but given stable hemologobin and known colitis on CT which can cause positive occult blood, further GI workup was not completed but this will be followed closely as an outpatient. Patient was discharged home in stable condition with plans to get outpatient labs 5/11 and be seen in clinic next week.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Dehydration
Hospital-Tage
7,0
Labordaten
-
Aktuelle Erkrankungen
None
Vorgeschichte
COPD, very severe (HCC) Other specified anxiety disorders Osteopenia of multiple sites Essential hypertension Need for prophylactic antibiotic Need for pneumocystis prophylaxis Skin lesions Bilateral lung transplant Other chronic pain Steroid-induced hyperglycemia Unspecified severe protein-calorie malnutrition (HCC) Infection due to Stenotrophomonas maltophilia in native lung Achromobacter infection in native lung Immunosuppressed status (HCC) Dysphagia AKI (acute kidney injury) (HCC) Diarrhea Cough Neutropenia (HCC) Staphylococcal pneumonia (HCC) COVID
Andere Medikamente
azithromycin (ZITHROMAX) 250 MG tablet benzonatate (TESSALON) 100 MG capsule Blood Glucose Monitoring Suppl (ONETOUCH VERIO) w/Device KIT cefuroxime (CEFTIN) 500 mg tablet cetirizine (ZYRTEC) 10 MG tablet cholecalciferol (VITAMIN D3) 50 MCG
Allergien
NsaidsOther OxycodoneAgitation
Vorherige Impfungen
-

VAERS 2109619

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

moderat
Staat
OK
Alter
69,0
Geschlecht
F
Eingang
14.02.2022
Impfdatum
11.02.2022
Beginn
12.02.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
SYR / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Asthenia Burning sensation Fatigue Headache Nausea Chills Cough Pain Pain of skin Pyrexia Skin burning sensation Tachycardia Paraesthesia

Symptomtext

Fever for 48 hours ranging from 100.1 to 100.8 Headache Fatigue Burning and tingling on entire body Weakness in joints Nausea

Weitere VAERSDATA-Felder
Praegender Schweregrund
Tachycardia
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
No illness prior
Vorgeschichte
Ulcerative colitis, Mast Cells activation syndrome
Andere Medikamente
Benedryl (pre vaccine)
Allergien
Yeast, peanuts, rice, corn, cinnamon, hair dye
Vorherige Impfungen
-

VAERS 2290470

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
NC
Alter
25,0
Geschlecht
F
Eingang
23.05.2022
Impfdatum
10.05.2022
Beginn
22.05.2022
Tage bis Beginn
12,0
Dosis
N/A
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema Injection site pain Myalgia Pyrexia Rash Rash maculo-papular

Symptomtext

Patient received 4 vaccines, reports no AEFI immediately after. At day 12 after vaccination, patient reports subjective fever, myalgias, a 5x7cm red area around VAR injection site with 5/10 pain, and a maculopapular rash (2 papules on lower back, 1 on neck). Patient also reports "bumps" on her scalp but unable to find on PE.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
None
Aktuelle Erkrankungen
None reported
Vorgeschichte
None reported
Andere Medikamente
None reported
Allergien
NKA
Vorherige Impfungen
-

VAERS 2276184

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge n254c

mild
Staat
AR
Alter
11,0
Geschlecht
F
Eingang
13.05.2022
Impfdatum
10.05.2022
Beginn
11.05.2022
Tage bis Beginn
1,0
Dosis
6
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Injection site erythema Injection site pain Injection site swelling

Symptomtext

redness, swelling and pain at injection site that started on 05/11/22.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2255073

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
UT
Alter
35,0
Geschlecht
F
Eingang
27.04.2022
Impfdatum
18.04.2022
Beginn
19.04.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site erythema Injection site urticaria Local reaction

Symptomtext

Patient returned to clinic on 04/20/22 (2 days following Tdap vaccination for a different vaccine that was needed. Patient showed injection site form Tdap and said she started to notice the red welt the day before 04/19/22. Provider and pharmacist came to assess the site and decided it was a localized reaction.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site erythema
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
ADHD depression meibomian gland dysfunction or upper and lower eyelids genital herpes simplex chronic idiopathic urticaria myopia of both eyes
Andere Medikamente
adderall yasmin valacyclovir epinephrine diphenhydramine clindamycin
Allergien
penicillins
Vorherige Impfungen
-

VAERS 2204337

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge n254c

mild
Staat
MO
Alter
25,0
Geschlecht
F
Eingang
29.03.2022
Impfdatum
20.03.2022
Beginn
20.03.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Hypoaesthesia Pain in extremity

Symptomtext

Arm soreness and numbness going on 9 days not resolving.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain in extremity
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2197145

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
CA
Alter
34,0
Geschlecht
F
Eingang
24.03.2022
Impfdatum
23.03.2022
Beginn
23.03.2022
Tage bis Beginn
0,0
Dosis
N/A
Route/Site
IM / RA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Chills Nausea Pain Retching

Symptomtext

Pt. reported acute onset nausea with dry heaves, chills and body aches. Treated originally treated with Zofran ODT, then IV fluids ( 1 L Normal Saline), IV meds: Benedryl, Pepcid and Solumedrol. 2 hrs after onset of symptoms, pt reports she is feeling better, nausea, chills and body aches resolved.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Chills
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
SKyla IUD
Allergien
Polymyxin B
Vorherige Impfungen
-

VAERS 2189890

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
CA
Alter
39,0
Geschlecht
F
Eingang
21.03.2022
Impfdatum
16.03.2022
Beginn
18.03.2022
Tage bis Beginn
2,0
Dosis
N/A
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Pain Skin warm Swelling

Symptomtext

Severe soreness, swelling of deltoid muscle, and warm to touch of the deltoid occurred on Friday, March 18, 2022, 3 days post-vaccination.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
None
Vorgeschichte
None
Andere Medikamente
none
Allergien
losartan. procardia
Vorherige Impfungen
-

VAERS 2177333

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge n254c

mild
Staat
CT
Alter
41,0
Geschlecht
M
Eingang
13.03.2022
Impfdatum
26.02.2022
Beginn
27.02.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site pain

Symptomtext

patient reported arm pain from injection site that has not gone away since recieving on the shot on 2.26

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
metformin lansoprazole
Allergien
no known allergies
Vorherige Impfungen
-

VAERS 2171266

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
VA
Alter
22,0
Geschlecht
F
Eingang
10.03.2022
Impfdatum
08.03.2022
Beginn
08.03.2022
Tage bis Beginn
0,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: ja
Abdominal pain Exposure during pregnancy Hypersensitivity Immunisation reaction Vomiting

Symptomtext

pt started throwing up and experiening severe abdominal pain. She is 36 weeks pregnant. ER doctor diagnosed her with allergic reaction to vaccine.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Abdominal pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
none
Vorgeschichte
epilepsy
Andere Medikamente
keppra 750mg
Allergien
latex and eggs
Vorherige Impfungen
-

VAERS 2168925

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
TX
Alter
59,0
Geschlecht
F
Eingang
09.03.2022
Impfdatum
04.03.2022
Beginn
06.03.2022
Tage bis Beginn
2,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: unbekannt
Decreased appetite Fatigue Inflammation Pyrexia Skin reaction

Symptomtext

Red, inflamed left arm, fever, fatigue, loss of appetite

Weitere VAERSDATA-Felder
Praegender Schweregrund
Fatigue
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
DIABETES
Andere Medikamente
OMPERAZOLE, ATORVASTATIN, LISINOPRIL, GLIPIZIDE
Allergien
-
Vorherige Impfungen
-

VAERS 2168272

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
CA
Alter
65,0
Geschlecht
F
Eingang
09.03.2022
Impfdatum
24.02.2022
Beginn
25.02.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Eye swelling Fatigue Nausea Pyrexia SARS-CoV-2 test negative Swelling face

Symptomtext

Pt. is a 65 Y female who reports that after she got her vaccines on 2/24 she was a little bit nauseated. She came home and felt very tired. She took a COVID test and it was negative. She started to see some swelling on the left side of the face last night. It was very pronounced and her left eye was nearly shut due to the swelling. It has gone down since yesterday. No rash. No difficulty breathing. No irritation of her throat. She did run a little fever yesterday into today. She did not take any photos. Today she feels there is still a little bit of swelling but not much.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Fatigue
Hospital-Tage
-
Labordaten
None known
Aktuelle Erkrankungen
None known
Vorgeschichte
-
Andere Medikamente
None known
Allergien
None known
Vorherige Impfungen
-

VAERS 2121152

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

mild
Staat
TX
Alter
55,0
Geschlecht
F
Eingang
17.02.2022
Impfdatum
14.02.2022
Beginn
15.02.2022
Tage bis Beginn
1,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Injection site pain Injection site swelling Injection site warmth

Symptomtext

Patient had pain, swelling, and warm to touch at injection site.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Injection site pain
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
sickle cell trait
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2361183

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

gering
Staat
MA
Alter
68,0
Geschlecht
M
Eingang
07.07.2022
Impfdatum
17.05.2022
Beginn
01.06.2022
Tage bis Beginn
15,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Wrong product administered

Symptomtext

PATIENT CAME INTO THE PHARMACY WITH INTENTIONS OF RECEIVING A 2ND COVID BOOSTER BUT WAS GIVEN A BOOSTRIX VACCINE. PATIENT CHECKED SYSTEM AND NOTICED THAT THE 2ND COVID BOOSTER WAS NOT AVAILABLE. PATIENT WAS DUE FOR HIS BOOSTRIX TETANUS SHOT AND WAS INFORMED TO RETURN TO PHARMACY ASAP TO GET SECOND COVID BOOSTER. PATIENT ENDED UP GETTING COVID BEFORE HE WAS ABLE TO RECIEVED HIS SECOND COVID BOOSTER.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Wrong product administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
N/A
Vorgeschichte
N/A
Andere Medikamente
N/A
Allergien
N/A
Vorherige Impfungen
-

VAERS 2329684

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

gering
Staat
HI
Alter
86,0
Geschlecht
F
Eingang
23.06.2022
Impfdatum
25.04.2022
Beginn
25.04.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
SYR / OT
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered Incorrect route of product administration

Symptomtext

NURSE WAS DISTRACTED AND GAVE THE VACCINE VIA IV ROUTE, NOT IM. AFTER THIS WAS REALIZED, SHE NOTIFIED THE MD WHO SAID TO GIVE ANOTHER DOSE IM. SO PATIENT GOT 2 DOSES OF BOOSTRIX ON 4/25/22. NO ADE WAS NOTED PRIOR TO DISCHARGE.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2211395

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

gering
Staat
CA
Alter
74,0
Geschlecht
M
Eingang
01.04.2022
Impfdatum
28.03.2022
Beginn
29.03.2022
Tage bis Beginn
1,0
Dosis
1
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: ja Erholt: ja
Anal incontinence Brain scan normal Fall Muscle disorder

Symptomtext

Patient experience loss of muscle control and fell down on his buttocks, as well as loss of bowel control. Patient says he experienced at least 3 bowel movements. After at least 1+ hour of loss of muscle control, he was able to call for an ambulance. At the hospital, they ran a head scan and found no abnormal brain activity, so the hospital staff thinks it may be related to the vaccine he received the day before.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Anal incontinence
Hospital-Tage
-
Labordaten
At the hospital, they ran a head scan and found no abnormal brain activity, so the hospital staff thinks it may be related to the vaccine he received the day before.
Aktuelle Erkrankungen
-
Vorgeschichte
HIV INFECTION, MIGRAINE, PRURITIS, VERTEBRAL DISK DISEASE
Andere Medikamente
-
Allergien
ASPIRIN
Vorherige Impfungen
-

VAERS 2192838

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

gering
Staat
CA
Alter
65,0
Geschlecht
M
Eingang
22.03.2022
Impfdatum
18.03.2022
Beginn
18.03.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
IM / LA
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: ja
Epistaxis Haematochezia

Symptomtext

Patient reported bloody nose on Friday night. It didn't stop bleeding for about 45 minutes. Patient also reported blood in stool. Pt states that he does not have a hx of bloody nose.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Epistaxis
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
Losartan, Levothyroxine, Albuterol
Allergien
Spinach, Wheat
Vorherige Impfungen
-

VAERS 2164927

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

gering
Staat
CA
Alter
30,0
Geschlecht
F
Eingang
08.03.2022
Impfdatum
02.03.2022
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

Boostrix administered after temp excur; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 30-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number N254C, expiry date 23rd November 2023) for prophylaxis. On 2nd March 2022, the patient received Boostrix. On an unknown date, unknown after receiving Boostrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. Additional details were reported as follows: The reporter reported that Boostrix underwent above temperature excursion with high 67 Fahrenheit for 14 days and was administered to a patient, which let to Incorrect storage of drug. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. This is 1 of the 6 cases reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2022040251:Same reporter US-GLAXOSMITHKLINE-US2022040252:Same reporter US-GLAXOSMITHKLINE-US2022040254:Same reporter US-GLAXOSMITHKLINE-US2022040246:Same reporter US-GLAXOSMITHKLINE-US2022040248:Same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2162289

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge n254c

gering
Staat
CA
Alter
26,0
Geschlecht
F
Eingang
07.03.2022
Impfdatum
02.03.2022
Beginn
-
Tage bis Beginn
-
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product storage error

Symptomtext

boostrix underwent above temp excur and was administered; This case was reported by a other health professional via call center representative and described the occurrence of incorrect storage of drug in a 26-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number n254c, expiry date 23rd November 2023) for prophylaxis. On 2nd March 2022, the patient received Boostrix. On an unknown date, unknown after receiving Boostrix, the patient experienced incorrect storage of drug. On an unknown date, the outcome of the incorrect storage of drug was unknown. Additional details were reported as follows: The reporter reported that the Boostrix underwent above temperature excursion with high: 67 F time: 14 days and was administered to the patient, which let to incorrect storage of drug. The vaccine administration facility was the same as primary reporter. The reporter consented to follow up. This was 1 of the 6 cases reported by the same reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2022040253:Same reporter US-GLAXOSMITHKLINE-US2022040254:Same reporter US-GLAXOSMITHKLINE-US2022040251:Same reporter US-GLAXOSMITHKLINE-US2022040252:Same reporter US-GLAXOSMITHKLINE-US2022040248:same reporter

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product storage error
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2141961

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge n254c

gering
Staat
FL
Alter
3,0
Geschlecht
F
Eingang
26.02.2022
Impfdatum
18.02.2022
Beginn
18.02.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Product administered to patient of inappropriate age

Symptomtext

Dose administered to 3 year old patient; This case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 3-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number n254c, expiry date 23rd November 2023) for prophylaxis. On 18th February 2022, the patient received Boostrix. On 18th February 2022, unknown after receiving Boostrix, the patient experienced inappropriate age at vaccine administration. On an unknown date, the outcome of the inappropriate age at vaccine administration was unknown. Additional details were provided as follows: The patient was inadvertently administrated a dose of Boostrix, which led to inappropriate age at vaccine administration. No further events were reported. The reporter agreed to be contacted for follow-up The Vaccine Administration Facility is the same as Primary Reporter.

Weitere VAERSDATA-Felder
Praegender Schweregrund
Product administered to patient of inappropriate age
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-

VAERS 2125740

GLAXOSMITHKLINE BIOLOGICALS · TDAP (BOOSTRIX) · Charge N254C

gering
Staat
IL
Alter
26,0
Geschlecht
F
Eingang
19.02.2022
Impfdatum
29.01.2022
Beginn
29.01.2022
Tage bis Beginn
0,0
Dosis
UNK
Route/Site
- / -
Tod: unbekannt Lebensbedrohlich: unbekannt Hospital: unbekannt Disable: unbekannt ER: unbekannt Erholt: nein
Extra dose administered

Symptomtext

dose in 2021 received another dose; This case was reported by a other health professional via call center representative and described the occurrence of extra dose administered in a 26-year-old female patient who received DTPa (Reduced antigen) (Boostrix) (batch number N254C, expiry date 23rd November 2023) for prophylaxis. Co-suspect products included dtpa vaccine. pre-filled syringe device (Boostrix Pre-Filled Syringe Device) injection syringe for prophylaxis. Previously administered products included Boostrix with an associated reaction of exposure during pregnancy (received 1st dose during pregnancy, refer linked case US2022016944). On 29th January 2022, the patient received Boostrix and Boostrix Pre-Filled Syringe Device. On 29th January 2022, unknown after receiving Boostrix and Boostrix Pre-Filled Syringe Device, the patient experienced extra dose administered. On an unknown date, the outcome of the extra dose administered was unknown. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional details were provided as follows: The Medical Assistant reported that, a pregnant patient received a dose of Boostrix in September 2021 and delivered on 14th November 2021. The patient returned for her postpartum visit on 29th January 2022 and received another dose of Boostrix, which led to extra dose administered. The reporter consented to follow up. The Vaccine Administration Facility is the same as Primary Reporter.; Sender's Comments: US-GLAXOSMITHKLINE-US2022016944:Same reporter and patient

Weitere VAERSDATA-Felder
Praegender Schweregrund
Extra dose administered
Hospital-Tage
-
Labordaten
-
Aktuelle Erkrankungen
-
Vorgeschichte
-
Andere Medikamente
-
Allergien
-
Vorherige Impfungen
-